Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 30, 2021
Event: Entry into a Material Definitive Agreement (Equity Financing Facility).
Key Financial Metrics and Transaction Terms
This filing details a new equity financing facility rather than reporting standard operational financial metrics (revenue, profit, cash flow) for a specific period.
- Total Commitment: Up to $5,000,000 in common stock purchases over a 36-month term.
- Purchase Price: 92% of the lowest trading price of the common stock during the five business days prior to the Closing Date.
- Commitment Fee: 1,000,000 restricted shares of common stock issued to the investor (Dutchess Capital Growth Fund LP).
- Draw Down Limits: Maximum of $250,000 or 300% of the average daily share volume per single draw down notice.
- Ownership Cap: Investor cannot acquire more than 4.99% of issued and outstanding shares.
Material Changes and Conditions
The primary material change is the establishment of the "Equity Line" with Dutchess Capital Growth Fund LP. Key conditions include:
- Effectiveness Condition: The investor is not obligated to purchase shares until a Registration Statement on Form S-1 becomes effective.
- Discretionary Draws: The Company may request purchases at its sole discretion, subject to the limitations above.
- Termination: The agreement terminates automatically after 36 months from the effective date of the Registration Statement or upon reaching the $5,000,000 Total Commitment.
Outlook, Risks, and Contingencies
Management Commentary: The Company is relying on exemptions from registration requirements (Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D) for the issuance of shares under this agreement. A Registration Rights Agreement was also signed to register shares for resale.
Risks and Contingencies:
- Dilution: Issuance of up to $5,000,000 worth of shares plus 1,000,000 restricted shares for the commitment fee will result in shareholder dilution.
- Market Price Impact: The purchase price is based on a discount (92%) of the lowest trading price, which may impact market sentiment.
- Indemnification: The Company agreed to indemnify the investor against losses related to breaches of representations or warranties.
Investor Verification Checklist
- Verify the status of the Form S-1 Registration Statement required to activate the equity line.
- Review the impact of the 1,000,000 restricted shares issued as a commitment fee on current share count and dilution.
- Monitor the Company's ability to meet the 4.99% beneficial ownership cap for the investor.
- Assess the Company's current cash position and immediate need for capital given the 36-month term of the facility.